Substituted imidazo ring systems and methods

A compound of the Formula (I-1):

• wherein:
• X is alkylene optionally interrupted by one or more —O— groups;
• Z is —C(O)—;
• R1-1 is selected from the group consisting of:
• hydrogen,
• alkyl,
• aryl,
• alkylene-aryl,
• heteroaryl,
• alkylene-heteroaryl, and
• alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:
• halogen,
• cyano,
• nitro,
• alkoxy,
• dialkylamino,
• alkylthio,
• haloalkyl,
• haloalkoxy, and
• alkyl;
• R2 is selected from the group consisting of:
• hydrogen,
• alkyl,
• alkenyl,
• alkylene-Y-alkyl,
• alkyene-Y-alkenyl, and
• alkyl or alkenyl substituted by one or more substituents selected from the group consisting of hydroxyl and halogen;
• RA and RB are each independently selected from the group consisting of:
• hydrogen,
• alkyl,
• alkenyl,
• alkoxy, and
• alkylthio;
• or RA and RB are taken together to form either a fused aryl ring that is unsubstituted or substituted by one or more R groups, or a fused 5 to 7 membered saturated ring that is unsubstituted or substituted by one or more Ra groups;
• R is selected from the group consisting of:
• fluoro,
• alkyl,
• haloalkyl,
• alkoxy, and
• —N(R9)2;
• and
• Ra is selected from the group consisting of:
• halogen,
• hydroxy,
• alkyl,
• alkenyl,
• haloalkyl,
• alkoxy,
• alkylthio, and
• —N(R9)2;
• Y is selected from the group consisting of —O— and —S(O)0-2—;
• and
• R9 is selected from the group consisting of hydrogen and alkyl;
• or a pharmaceutically acceptable salt thereof.